靶向视黄酸(维甲酸)诱导基因蛋白-Ⅰ受体应用的研究进展  

Progress in research on application of molecular drug targeted on retinoic acid inducible gene-Ⅰlike receptors

作　　者：李克雷 吴星(综述)[1] 郑海发[2] 梁争论(审校)[1] LI Ke-lei;WU Xing;ZHENG Hai-fa;LIANG Zheng-lun(Department of Hepatitis Virus and Enterovirus,Rationed institutes for Food and Drug Control,Beijing 102629,China)

机构地区：[1]中国食品药品检定研究院肝炎病毒肠道病毒疫苗室,北京102629 [2]北京民海生物科技有限公司,北京102629

出　　处：《中国生物制品学杂志》2022年第1期95-99,共5页Chinese Journal of Biologicals

摘　　要：模式识别受体(pattern recognition receptor,PRR)具有激活固有免疫,诱导适应性免疫的重要作用。当PRR识别配体后,启动信号级联反应,诱导干扰素等细胞因子表达,从而触发适应性免疫系统的体液免疫和细胞免疫。由于PRR在免疫系统的关键作用,靶向PRR的配体成为潜在的候选药物或佐剂。其中,靶向视黄酸(维甲酸)诱导基因蛋白-Ⅰ(retinoic acid inducible gene-Ⅰ,RIG-Ⅰ)样受体(RIG-Ⅰ-like receptors,RLRs)的配体不仅可作为抗病毒和癌症治疗药物,还可作为佐剂应用于新型疫苗研发。作为新的药物靶点,RLRs越来越受到重视,本文就靶向RLRs的配体在抗病毒、癌症治疗及疫苗佐剂中的应用作一综述。Pattern recognition receptor(PRR)plays an important role in activating innate immunity and inducing adaptive immunity.When PRR recognizes the ligand,it starts the signal cascade reaction and induces the expression of cytokines such as interferon,which triggers the humoral and cellular immunity of adaptive immune system.Because of the key role of PRR in the immune system,the ligands targeting PRR have become potential candidates for drugs or adjuvants,among those targeting the retinoic acid inducible gene-Ⅰ(RIG-Ⅰ)-like receptors(RLRs)can not only be used as antiviral and cancer treatment drugs,but also as adjuvant used for new vaccine development.As a new target of drug research,RLRs are paid more and more attention.This paper reviews the application of ligands targeting RLRs in antiviral,cancer treatment and adjuvant.

关 键 词：RIG-Ⅰ样受体 抗病毒 免疫调节 

分 类 号：R392.12[医药卫生—免疫学]